MedTrace Logo

Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine

NCT01110044 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-03-27

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and immunogenicity of a birth dose of GSK Biologicals' reduced-antigen-content tri-component pertussis (251154) vaccine followed by routine paediatric vaccination.

Conditions

  • Infections, Rotavirus

Interventions

BIOLOGICAL

251154 vaccine

Intramuscular, single dose

BIOLOGICAL

Infanrix hexa™

Intramuscular, four doses

BIOLOGICAL

Synflorix™

Intramuscular, four doses

BIOLOGICAL

Rotarix™

Oral, two doses

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Days
Max Age
5 Days
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-08-31
Completion
2012-08-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01110044 on ClinicalTrials.gov